Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback